GC
IMUC

Guggenheim Capital’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Guggenheim Capital’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,984
Closed -$9K – 3097
2016
Q3 		$9K Buy
1,984
+1,038
+110% +$6.68K ﹤0.01% 2867
2016
Q2 		$9K Hold
946
– – ﹤0.01% 2854
2016
Q1 		$11K Buy
946
+467
+97% +$5.25K ﹤0.01% 2871
2015
Q4 		$7K Hold
479
– – ﹤0.01% 2958
2015
Q3 		$8K Buy
479
+60
+14% +$1.09K ﹤0.01% 2936
2015
Q2 		$8K Hold
419
– – ﹤0.01% 3026
2015
Q1 		$8K Buy
419
+108
+35% +$2.71K ﹤0.01% 3026
2014
Q4 		$9K Buy
+311
New +$8.95K ﹤0.01% 2995
2014
Q3 		– Sell
-569
Closed -$25K – 3307
2014
Q2 		$25K Sell
569
-57
-9% -$2.75K ﹤0.01% 3151
2014
Q1 		$31K Buy
626
+142
+29% +$6.94K ﹤0.01% 3193
2013
Q4 		$18K Buy
484
+29
+6% +$2.75K ﹤0.01% 3142
2013
Q3 		$47K Sell
455
-58
-11% -$6.37K ﹤0.01% 2943
2013
Q2 		$39K Buy
+513
New +$49.1K ﹤0.01% 2932

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $5.71M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return